The quarter ends on a quiet note, but the portfolio's ledger tells a louder story. Three positions closed in the last seven days — one winner, two losers — and the numbers land exactly where a systematic approach expects them to: a 33% win rate, a 3.4% average return, and an average hold of 44 days across the batch. That's the math of a strategy designed to keep losses small and let winners run. The portfolio currently holds 169 open positions across a 310-name qualified pool drawn from a 422-ticker universe. Most of those positions are doing what they're supposed to: grinding higher, getting stopped out cleanly, or waiting for the next catalyst.
The Closed Trades
CRWD delivered the headline: a +21.4% win over 35 days, closed September 24. The cybersecurity leader has been a recurring name in the qualified pool, and this exit captures a clean trend move — the kind that pays for a handful of smaller losses. If you're tracking CRWD stock analysis September 2026, this trade is a textbook example of what the system looks for: liquidity, momentum, and a clear exit when the tape changes character.
TXN exited September 28 with a -0.9% loss over 41 days. A near-flat outcome after six weeks is effectively the cost of admission — the small price paid to stay in the game for the outliers. The TXN stock analysis September 2026 shows a semiconductor name that chopped sideways while the broader sector rotated; the system recognized the lack of follow-through and moved on. That's the TXN trading signal doing its job: no drama, no bag-holding.
RL was the outlier on the downside: -10.2% over 55 days, closed September 25. Apparel retail has been a minefield of mixed guidance and inventory overhangs, and this position caught the wrong side of that narrative. The RL stock analysis September 2026 reflects a name that looked constructive on the setup but failed to sustain — a reminder that even high-quality setups fail at a predictable rate. The RL trading signal exited before the drawdown deepened, preserving capital for the next opportunity.
Two losses, one win. The portfolio's risk overlay — the proprietary layer that sits on top of every position — is built precisely for this distribution. Small losses are not failures; they're the expected friction of a process that targets asymmetric upside. The CRWD trading signal captured that asymmetry. The other two kept the downside contained.
Market Backdrop: Oil, Geopolitics, and a Quarter-End Snapshot
Headlines this morning are a mix of geopolitical tension and quarter-end positioning. Oil prices rose roughly $1 per barrel on stalled U.S.-Iran talks and tight fuel markets — a reminder that energy volatility remains a portfolio factor even when the equity tape is calm. In the Middle East, passengers foiled an apparent attempt to crash a Dubai-Tel Aviv flight after a co-pilot-on-pilot stabbing, prompting Israel to ramp up pilot checks and drawing a Saudi refusal to allow Israeli planes to retrieve stranded passengers. Separately, Israeli strikes in Gaza killed seven, per medics, while U.S. forces completed their withdrawal from Iraq, leaving what Reuters describes as a potential security vacuum.
On the corporate side, Eli Lilly reported mixed obesity-drug trial data as Wall Street wraps a strong quarter. Boeing landed a massive Navy contract, though the coverage noted skepticism from certain quarters about the near-term financial impact. MGM's CEO left the door open to a People Inc. bid as casino dealmaking heats up. And a CNBC piece highlighted two recent trades in Magnificent Seven names that "point to big gains ahead" — though, as always, the market will decide whether those setups play out.
What to Watch
BA (Boeing) — The defense giant secured a major Navy contract award, a multi-year program that adds visibility to the backlog. Commercial delivery headwinds and supply-chain constraints remain the overhang; watch for 737 MAX production rate updates and any revision to free-cash-flow guidance at the next quarterly call.
LLY (Eli Lilly) — Mixed results from the latest obesity-drug trial introduced a rare note of caution into the GLP-1 narrative. The compound showed efficacy but with a side-effect profile that may limit dosing flexibility. The street is recalibrating peak-sales models; the next catalyst is the full data presentation at a major medical conference next month.
MGM (MGM Resorts) — The CEO's public openness to a People Inc. bid signals that consolidation talks are active, not theoretical. Regional gaming assets are scarce, and scale matters for loyalty-program economics. Watch for a formal offer structure — cash versus stock — and any regulatory noise in key jurisdictions.
XOM / CVX (Energy Majors) — With crude up a dollar on geopolitical risk premium and tight distillate inventories, the integrated oils are back in focus. Both companies report in late October; the market will scrutinize Permian capital discipline, share-buyback pacing, and any commentary on strategic M&A appetite.
AAPL / MSFT / NVDA (Magnificent Seven Leaders) — The CNBC piece referencing "two trades" in this cohort aligns with elevated options flow in large-cap tech into quarter-end. No specific names were confirmed, but the pattern suggests institutional positioning for a Q4 rally. Earnings season kicks off in mid-October; guidance tone on enterprise AI spend and consumer upgrade cycles will set the tone.
If you want to see the full trade ledger — every win, every loss, every hold time — it's on the dashboard.